Debes de seleccionar un país
Inicio » Índice de Estudios Clínicos por Padecimiento » Irritable Bowel Syndrome (IBS)

Functional Gastrointestinal Disorders (FGIDs)


Irritable Bowel Syndrome (IBS)

Infant Colic – Management Infant Colic – Prevention Fifteen Meta-Analyses Supporting the Efficacy in Infant Colic Functional Abdominal Pain (FAP) in Children Meta-Analysis Supporting the Efficacy in Children with FAP Regurgitation in Infants Functional Constipation in Infants and Children Prevention of FGIDs in Infants Functional Constipation in Adults Irritable Bowel Syndrome (IBS)
Reference

Cruchet S, 2024
Chile / Mexico

Study Objectives

To evaluate efficacy and safety of L. reuteri DSM 17938 + ATCC PTA 6475 (Gastrus) on symptoms of IBS in adults.

Study Design*

R, DB, PC 14 weeks

No. of Subjects (dose)

L. reuteri: 70 (4×108 CFU) Placebo: 70

Results

L. reuteri Gastrus significantly improved overall IBS symp toms (GSRS-IBS score), individual scores (abdominal pain, pain relieved by a bowel action, bloating, passing gas, visible distension), Quality of Life and anxiety from treatment week 6 and onwards.

Reference

Niv E, 2005
Israel

Study Objectives

To evaluate L. reuteri for treatment of mixed type IBS in adults.

Study Design*

R, DB, PC 6 months

No. of Subjects (dose)

L. reuteri: 27 (2×108 CFU) Placebo: 27

Results

Compared to placebo, L. reuteri showed strong tendency to effect on:
• Reduced gases
• Reduced constipation Study limitations: underpowered, due to only one study center of two started and completed the study